FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, I	D.C.	20549
---------------	------	-------

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

l	OMB APPRO	DVAL
	OMB Number:	3235-0287
l	Estimated average burd	en
l	hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* GLAXOSMITHKLINE PLC				2. Issuer Name and Ticker or Trading Symbol THERAVANCE INC [THRX]								Relationship of Reporting Person(s) to Issuer (Check all applicable) Director							
(Last) 980 GRE	(Fi	,	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 10/29/2013								Office below	er (give w)	title		Other (selow)	specify	
(Street) BRENTF MIDDLE	ESEX X		TW8 9GS	4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Lii	Individual or Joint/Group Filing (Check Applicable le) X Form filed by One Reporting Person Form filed by More than One Reporting Person							
(City)	(5)		(Zip)	votivo	Coo	:4:.			rad Die		-	or Done	ficia	Illy Overs					
Date (Month/Day/Year) if a			2A. Dee Executi if any	A. Deemed 3. Execution Date, Trans		i. Transac Code (li	tion	4. Securities Ad Of (D) (Instr. 3, str.		uired (A) or Disposed					6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Common Stock 10/29/2013			10/29/2013				P		130,47	B ⁽¹⁾ A	\$4,913,613.18		.3.18	3 29,916,073		I		By Corp	oration ⁽²⁾
		Т	able II - Deriva (e.g., p							osed of, onvertib				/ Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of Deriv Secu Acqu (A) o Disp of (D	vative (Month/D irities aired osed) r. 3, 4				7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4) Amoun or Numbe of Title Shares		ount ober	8. Price of Derivative Security (Instr. 5)			10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Common stock purchased pursuant to the right of GlaxoSmithKline LLC ("GSK LLC") under Section 2.1(d)(ii) and 2.1(d)(v) of the Amended and Restated Governance Agreement by and among Theravance, Inc. (the "Issuer"), GSK LLC, Glaxo Group Limited and GlaxoSmithKline plc dated as of June 4, 2004, as amended. Pursuant to Section 2.1(d)(ii), GSK LLC has the right to purchase from the Issuer, on a quarterly basis, sufficient shares of common stock to maintain its ownership percentage in the Issuer taking into account the preceding quarter's option exercise and equity vesting activity. Pursuant to Section 2.1(d)(v), GSK LLC has the right to purchase from the Issuer sufficient shares of common stock to maintain its ownership percentage in the Issuer as a result of the conversion of certain of the Issuer's convertible indebtedness

2. Shares of Common Stock are held of record by Glaxo Group Limited, an indirect wholly owned subsidiary of GlaxoSmithKline plc.

/s/ Simon Dingemans, Chief **Financial Officer**

10/29/2013

Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.